View Older Stories View More Recent Stories
-
Novartis (NOVN:SW) (NVS) PT Lowered to CHF105 at Berenberg
-
Artisan Partners calls for Novartis board changes amid trial, acquisition failures
-
Artisan Partners calls for board shake-up at Novartis after drug trial setbacks - Reuters
-
HSBC Upgrades Novartis (NOVN:SW) (NVS) to Hold
-
RBC Capital Starts Novartis (NOVN:SW) (NVS) at Sector Perform
-
CLSA Reiterates Outperform (2) Rating on Novartis (NOVN:SW) (NVS)
-
Deutsche Bank Downgrades Novartis (NOVN:SW) (NVS) to Hold Following Today's 13% Selloff
-
Novartis DM1 drug trial misses primary endpoint in Phase III study
-
Novartis (NVS) call put ratio 1.6 calls 1 put into share price lower before the bell
-
Novartis pelacarsen trial fails to meet primary endpoint
-
Novartis MS drug remibrutinib meets Phase III trial goals
-
FDA approves Novartis Pluvicto for earlier-stage prostate cancer
-
JPMorgan Reiterates Overweight Rating on Novartis (NOVN:SW) (NVS)
-
Novartis CEO says will stay with drugmaker for next growth phase
-
Novartis (NVS) Tops Q2 EPS by 23c; offers outlook
-
Novartis wins EU approval for SMA gene therapy in older patients
-
Increasing unusual put volume: STRC EWA HTZ EIX NVS SITM WEN STWD VSH PENG ZIM
-
Antares Therapeutics and Novartis team up on cancer drug discovery
-
German government to drop variable drug discounting plans - Reuters
-
Novartis drug shows efficacy in chronic urticaria trial
-
Novartis reports positive biomarker results for experimental FSHD treatment
-
Novartis to present Rhapsido data at allergy congress
-
Novartis reports kidney function benefits for IgAN drug in phase III trial
-
Novartis reports positive 144-week data for Scemblix in CML trial
-
China holds roundtable with over 50 foreign pharmaceutical firms
-
China Commerce Ministry holding meeting with foreign pharma companies including Lilly, Sanofi, Novartis, Merck
-
Novartis breaks ground on Texas radioligand therapy manufacturing site
-
Novartis receives Health Canada approval for Fabhalta® oral treatment for adults with C3G
-
Novartis announces new API manufacturing facility in North Carolina
-
Novartis completes seventh US facility plan with North Carolina site
-
Novartis wins positive EU opinion for SMA gene therapy Itvisma
-
Novartis expands health programs to reach underserved communities globally
-
Novartis reports positive two-year results for Fabhalta in kidney disease
-
Novartis to acquire biotech Excellergy for up to $2 billion
-
Novartis to present immunology data at dermatology meeting
-
Novartis to acquire breast cancer drug developer for up to $3 billion
-
Novartis taps debt markets to fund $12 billion Avidity acquisition
-
Novartis gets FDA approval for Cosentyx in pediatric hidradenitis suppurativa
-
Argus Upgrades Novartis (NVS) to Buy
-
Increasing unusual call option volume: NVS BRBR BNO OMC QGEN SCO CGNX WEAT ZVRA
-
Novartis shareholders approve 5.7% dividend increase at annual meeting
-
Novartis receives positive European opinion for CSU treatment remibrutinib
-
Novartis reports positive results for remibrutinib in chronic urticaria
-
Novartis (NVS) PT Raised to $180 at TD Cowen
-
Novartis CEO says company likely shielded from U.S. tariffs
-
FDA grants Breakthrough Therapy status to Novartis ianalumab for Sjögren's
-
Novartis licenses peptide asset from PepLib for radioligand therapy
-
Barclays Upgrades Novartis (NVS) to Equalweight
-
Drugmakers Raise Us Prices On 350 Medicines Despite Pressure From Trump - Reuters
-
Novartis reaches agreement with US government on drug pricing measures
